MESO Q1 2020 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+45.0% YoY

Gross Profit

$14M84.0% margin

Operating Income

-$4M-20.8% margin

Net Income

-$5M-32.5% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+757.8%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$804,000

Balance Sheet

Total Assets

$654M

Total Liabilities

$179M

Stockholders' Equity

$475M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$12M	+45.0%
Gross Profit	$14M	$7M	+93.6%
Operating Income	-$4M	-$17M	+79.1%
Net Income	-$5M	-$19M	+71.9%